LAS VEGAS, May 09, 2019 (GLOBE NEWSWIRE) -- Item
9 Labs Corp. (INLB) (âItem 9 Labsâ or the
âCompanyâ), a leader in comfortable cannabis health solutions for
the modern consumer, today announced its medical cannabis
cultivation and processing facility Strive Wellness of Nevada will
prioritize sustainable initiatives throughout
Item 9 Labs broke ground on the project in April
2019 and will be producing legal medical cannabis products under
organic practices by Q4. Located in Pahrump, Nevada, the
20,000 square-foot operation includes distribution rights.
âIt is incredibly rewarding to see
the Nevada cultivation and processing facility come to
life,â stated CEO Sara Gullickson. âUltimately, this license led me
to forge my partnership with Item 9 Labs, which has evolved into a
strong relationship of shared values and vision. Together, we are
bringing best of industry practices to operations across the
In November 2018, Item 9 Labs partnered with
Bowden Investment Group to assist with environmentally friendly
building strategies. The group is noted for constructing the first
100% sustainable apartment complex in Scottsdale, Arizona.
âWith such a great and natural product under the
roof, it only makes sense to combine a sustainable approach to the
way we build and outfit the facility with the best materials and
the latest, most efficient equipment for growing,â stated Andrew
Bowden, CEO of Bowden Investment Group and Item 9 Labs board
Bowden Investment Group is currently enhancing
Item 9 Labsâ Arizona cultivation and processing facility by
introducing state-of-the-art custom environmental and irrigation
controls, as well as an upgraded lighting system to increase
efficiency and reduce energy use.
Item 9 Labs will be operating as licensed
dispensaries, cultivation, and manufacturing facilities in a
projected six to ten U.S. markets by the end of 2019.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (INLB)
creates comfortable cannabis health solutions for the modern
consumer. The Company is bringing best of industry practices to
markets from coast to coast through cultivation and production,
distinctive retail environments, licensing services, and diverse
product suites catering to different medical cannabis demographics.
Item 9 Labs Corp. is headquartered in Phoenix, Arizona, with
medical cannabis operations in multiple U.S. markets.
Item 9 Labs Corp.âs asset portfolio includes
Dispensary Permits, Dispensary Templates, and Strive Life. These
assets provide services specific to different stakeholder groups.
Dispensary Permits is the Companyâs consulting firm specializing in
strategic license application and compliance. Dispensary Templates,
a subdivision of the firm, is a technology platform with an
extensive digital library of licensing and business planning
resources. Strive Life is a turnkey dispensary model for the retail
sector, elevating the patient experience with consistent and
superior service, high-end design, and precision-tested products.
It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the
industry with its dynamic product suites. The Company has created
complementary brands Item 9 Labs and Strive Wellness to channel
consumer diversity. Propriety delivery platforms include the Apollo
Vape and Pod system, as well as a pioneering intra-nasal device.
The Company has received multiple accolades for its medical-grade
flower and concentrates.
Item 9 Labs Corp. will be managing cultivation,
processing, distribution, and dispensary operations in up to ten
U.S. markets by the end of 2019. Current facilities include
distribution and processing operations Strive Wellness of Ohio and
Strive Wellness of Nevada, as well as dispensary Strive Life North
For more information, visit Item 9 Labs Corp.
Statement: This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements involve risks and uncertainties, including, but not
limited to, risks and effects of legal and administrative
proceedings and governmental regulation, especially in a foreign
country, future financial and operational results, competition,
general economic conditions, proposed transactions that are not
legally binding obligations of the company and the ability to
manage and continue growth. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual outcomes may vary materially from those
indicated. Important factors that could cause actual results to
differ materially from the forward-looking statements we make in
this news release include the introduction of new technology,
market conditions and those set forth in reports or documents we
file from time to time with the SEC. We undertake no obligation to
revise or update such statements to reflect current events or
circumstances after the date hereof or to reflect the occurrence of
Item 9 Labs Corp.